CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Percheron Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Percheron Therapeutics Ltd
L30, Collins Place, 35 Collins Street
Phone: +61 398278999p:+61 398278999 MELBOURNE, VIC  3000  Australia Ticker: PERPER
Business Summary
Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board CharmaineGittleson 8/7/2023 3/22/2021
Chief Executive Officer, Managing Director, Executive Director James B.Garner 50 8/7/2023 5/8/2023
Chief Financial Officer, Joint Company Secretary DeborahAmbrosini 6/17/2024 6/17/2024
5 additional Officers and Directors records available in full report.

Business Names
Business Name
ANP
Antisense Therapeutics Limited
ATHJ
4 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 6/30/2014)
Outstanding Shares: 901,544,971 (As of 6/30/2024)
Shareholders: 3,460
Stock Exchange: ASX
Fax Number: +61 398597701


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024